Regencell Faces Class Action Lawsuit for Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 03 2026
0mins
Source: Globenewswire
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Regencell Bioscience Holdings Ltd. to recover damages for investors who purchased securities between October 28, 2024, and October 31, 2025, indicating significant legal risks for the company.
- False Statements Allegations: The complaint alleges that executives made materially false and misleading statements during the class period, failing to disclose risks of market manipulation, which exposed investors to substantial financial risks and could harm the company's reputation and market trust.
- Increased Regulatory Risks: The volatility in the market has heightened the risk of regulatory scrutiny and enforcement actions against Regencell, potentially leading to significant legal, financial, and reputational harm that could further impact the company's operations.
- Investor Rights Protection: Investors have until June 23, 2026, to request to be appointed as lead plaintiff, with the law firm offering legal support on a contingency fee basis, ensuring that investor rights are upheld and protected.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGC
About RGC
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regencell Faces Class Action Lawsuit for Securities Fraud
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Regencell Bioscience Holdings Ltd. to recover damages for investors who purchased securities between October 28, 2024, and October 31, 2025, reflecting concerns over potential market manipulation.
- Allegations of False Statements: The complaint alleges that executives made materially false and misleading statements during the class period, failing to disclose the company's vulnerability to market manipulation, which exposed investors to significant financial risks and legal repercussions.
- Legal Risks and Consequences: The heightened risk of regulatory scrutiny and enforcement actions against the company could lead to substantial legal, monetary, and reputational harm for investors, exacerbating the crisis of confidence in the company's future.
- Investor Rights Protection: Investors have until June 23, 2026, to request lead plaintiff status, and the law firm operates on a contingency fee basis, ensuring that investors' rights are protected in the legal proceedings.
See More
Regencell Faces Class Action Lawsuit for Investor Rights
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Regencell in the U.S. District Court for Maryland on behalf of investors who purchased securities between October 28, 2024, and October 31, 2025, indicating significant legal risks for the company.
- Allegations of False Statements: The lawsuit alleges that Regencell made false and misleading statements regarding its business operations and compliance policies, exposing investors to substantial financial risks and potential regulatory scrutiny.
- Investor Rights Protection: Investors must apply by June 23, 2026, to be appointed as lead plaintiffs in the lawsuit, highlighting the importance of protecting the rights of affected investors in this case.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in shareholder rights, offering no-cost legal consultations to help investors understand their rights and options regarding the lawsuit.
See More
Regencell Securities Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, that they must apply to be lead plaintiff by June 23, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to market manipulation and significant financial risks, potentially leading to legal and reputational harm.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its successful track record and extensive experience in this field.
- Investor Rights Protection: Investors can participate in the lawsuit without any out-of-pocket fees through Rosen Law Firm, ensuring their rights are protected in any potential future recovery.
See More
Regencell Investors Reminded of Class Action Deadline
- Lawsuit Background: Regencell Bioscience Holdings Limited is facing a class action lawsuit for failing to disclose market manipulation risks during the period from October 28, 2024, to October 31, 2025, with investors able to file as lead plaintiffs by June 23, 2026, to seek compensation.
- Legal Investigation: On October 31, 2025, Regencell revealed it received a subpoena from the U.S. Department of Justice indicating an investigation into its ordinary share trading, with expectations of incurring significant legal costs and potential fines, exacerbating financial risks for investors.
- Stock Price Volatility: Following the investigation announcement, Regencell's stock price fell by $3.09, or 18.56%, on November 3, 2025, directly causing investor losses and reflecting a crisis of market trust in the company.
- Disclosure Failures: The lawsuit alleges that throughout the class period, the company failed to disclose significant financial and legal risks, leading investors to hold an overly optimistic view of the company's prospects, which may trigger broader regulatory scrutiny.
See More
Regencell Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to participate in the class action without any out-of-pocket fees.
- Legal Risks Exposed: The lawsuit alleges that Regencell made false and misleading statements during the Class Period, exposing investors to market manipulation risks and significant financial losses, which could lead to regulatory scrutiny and legal repercussions.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its successful track record and extensive experience in this field.
- Investor Advisory: Investors are advised to carefully select legal counsel and avoid inexperienced intermediaries to ensure effective legal support and representation in the class action.
See More
Multiple Companies Face Class Action Lawsuits
- LKQ Corporation Lawsuit: LKQ faces a class action lawsuit for the period from February 27, 2023, to July 23, 2025, alleging that executives failed to disclose significant risks regarding customer losses and market share erosion, misleading investors and negatively impacting the company's reputation and stock price.
- Regencell Bioscience Lawsuit: During the class period from October 28, 2024, to October 31, 2025, Regencell is accused of not disclosing risks of market manipulation and financial exposure, which could lead to legal and reputational harm, increasing investor anxiety.
- Globant Lawsuit: Globant is facing a class action for the period from February 15, 2024, to August 14, 2025, due to failure to disclose decreasing demand in Latin America and wage freezes, severely undermining investor confidence in the company's prospects.
- Investor Rights Reminder: The Law Offices of Frank R. Cruz remind affected investors of the deadlines on June 22 and 23, 2026, encouraging them to participate in the lawsuits to protect their rights.
See More
Regencell Faces Class Action Lawsuit for Securities Fraud
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Regencell Bioscience Holdings Ltd. to recover damages for investors who purchased securities between October 28, 2024, and October 31, 2025, reflecting concerns over potential market manipulation.
- Allegations of False Statements: The complaint alleges that executives made materially false and misleading statements during the class period, failing to disclose the company's vulnerability to market manipulation, which exposed investors to significant financial risks and legal repercussions.
- Legal Risks and Consequences: The heightened risk of regulatory scrutiny and enforcement actions against the company could lead to substantial legal, monetary, and reputational harm for investors, exacerbating the crisis of confidence in the company's future.
- Investor Rights Protection: Investors have until June 23, 2026, to request lead plaintiff status, and the law firm operates on a contingency fee basis, ensuring that investors' rights are protected in the legal proceedings.
See More
Regencell Faces Class Action Lawsuit for Investor Rights
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Regencell in the U.S. District Court for Maryland on behalf of investors who purchased securities between October 28, 2024, and October 31, 2025, indicating significant legal risks for the company.
- Allegations of False Statements: The lawsuit alleges that Regencell made false and misleading statements regarding its business operations and compliance policies, exposing investors to substantial financial risks and potential regulatory scrutiny.
- Investor Rights Protection: Investors must apply by June 23, 2026, to be appointed as lead plaintiffs in the lawsuit, highlighting the importance of protecting the rights of affected investors in this case.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in shareholder rights, offering no-cost legal consultations to help investors understand their rights and options regarding the lawsuit.
See More
Regencell Securities Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, that they must apply to be lead plaintiff by June 23, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to market manipulation and significant financial risks, potentially leading to legal and reputational harm.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its successful track record and extensive experience in this field.
- Investor Rights Protection: Investors can participate in the lawsuit without any out-of-pocket fees through Rosen Law Firm, ensuring their rights are protected in any potential future recovery.
See More
Regencell Investors Reminded of Class Action Deadline
- Lawsuit Background: Regencell Bioscience Holdings Limited is facing a class action lawsuit for failing to disclose market manipulation risks during the period from October 28, 2024, to October 31, 2025, with investors able to file as lead plaintiffs by June 23, 2026, to seek compensation.
- Legal Investigation: On October 31, 2025, Regencell revealed it received a subpoena from the U.S. Department of Justice indicating an investigation into its ordinary share trading, with expectations of incurring significant legal costs and potential fines, exacerbating financial risks for investors.
- Stock Price Volatility: Following the investigation announcement, Regencell's stock price fell by $3.09, or 18.56%, on November 3, 2025, directly causing investor losses and reflecting a crisis of market trust in the company.
- Disclosure Failures: The lawsuit alleges that throughout the class period, the company failed to disclose significant financial and legal risks, leading investors to hold an overly optimistic view of the company's prospects, which may trigger broader regulatory scrutiny.
See More
Regencell Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, to apply as lead plaintiffs by June 23, 2026, to participate in the class action without any out-of-pocket fees.
- Legal Risks Exposed: The lawsuit alleges that Regencell made false and misleading statements during the Class Period, exposing investors to market manipulation risks and significant financial losses, which could lead to regulatory scrutiny and legal repercussions.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its successful track record and extensive experience in this field.
- Investor Advisory: Investors are advised to carefully select legal counsel and avoid inexperienced intermediaries to ensure effective legal support and representation in the class action.
See More
Multiple Companies Face Class Action Lawsuits
- LKQ Corporation Lawsuit: LKQ faces a class action lawsuit for the period from February 27, 2023, to July 23, 2025, alleging that executives failed to disclose significant risks regarding customer losses and market share erosion, misleading investors and negatively impacting the company's reputation and stock price.
- Regencell Bioscience Lawsuit: During the class period from October 28, 2024, to October 31, 2025, Regencell is accused of not disclosing risks of market manipulation and financial exposure, which could lead to legal and reputational harm, increasing investor anxiety.
- Globant Lawsuit: Globant is facing a class action for the period from February 15, 2024, to August 14, 2025, due to failure to disclose decreasing demand in Latin America and wage freezes, severely undermining investor confidence in the company's prospects.
- Investor Rights Reminder: The Law Offices of Frank R. Cruz remind affected investors of the deadlines on June 22 and 23, 2026, encouraging them to participate in the lawsuits to protect their rights.
See More
